MarketPeel
Insider Trading Intelligence
MA

Margaret A. Alexander

OVID
PRESIDENT AND COO · OVID THERAPEUTICS INC. · CIK 0002036798
FILING MIX · LIFETIME75%/25%
BUYS
6
SELLS
2
TOTAL VALUE
$24.8K
COMPANIES
1
ACTIVE SINCE
Sep 2024
HOLDINGS NOW
1,435,000
AVG SELL PX
$1.17
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 5 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Margaret A. Alexander, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+33.33%-0.59%-0.54%-0.05%-4.63%
14d3+33.33%+9.44%-1.90%+11.33%-1.01%
30d3+33.33%+1.36%-3.60%+4.97%-25.72%
60d3+33.33%-2.59%-3.15%+0.56%-27.84%
90d3+33.33%-9.24%-4.04%-44.98%-44.98%
180d3(1 pending)+0.00%+48.30%+7.50%+40.80%+40.80%
1y3(1 pending)+50.00%+177.10%+16.34%+160.76%+160.76%
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OVID · 1,435,000 shares · as of Feb 26, 2026
0358,750717,5001,076,2501,435,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2025
2025
2025
2025
2026
FLOW · 6 buys / 2 sellsCOVERAGE · 7 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
1,435,0001,435,000Feb 26, 2026Mar 2, 2026View →
OVID
OVID THERAPEUTICS INC.
SALE
President and CEO
11,656$1.45$16.9K61,750Feb 23, 2026Mar 2, 2026View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
890,000890,000Jan 4, 2026Jan 5, 2026View →
OVID
OVID THERAPEUTICS INC.
SALE
President and COO
5,279$0.56$3.0K73,406Feb 26, 2025Feb 28, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
43,75078,685Feb 20, 2025Feb 24, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
262,500262,500Feb 20, 2025Feb 24, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASE
President and COO
6,810$0.73$5.0K34,935Jan 27, 2025Jan 29, 2025View →
OVID
OVID THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
140,000140,000Sep 9, 2024Sep 11, 2024View →
Other insiders · OVID
Loading peer insiders…
About this filer
CIK 0002036798
ROLE
President and COO
PRIMARY
OVID
COMPANIES
1
ACTIVE SINCE
Sep 2024
MARKETPEEL · /INSIDER/0002036798DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback